Dara plus dex in R/R myeloma patients with renal impairment

The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myelomaПодробнее

R/R myeloma: iberdomide, dex & dara or bortezomibПодробнее

Pomalidomide + Low-Dose Dex + Dara in Relapsed and/or Refractory Multiple MyelomaПодробнее

$Pomalidomide + Low-Dose Dex + Dara in Relapsed and/or Refractory Multiple Myeloma$

Iberdomide in Combination with Dex and Dara, Bort, or Cfz in Pts with RRMMПодробнее

Multiple Myeloma - Case PresentationsПодробнее

Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairmentПодробнее

DARE: dara for R/R myeloma with renal impairmentПодробнее

DARA + pom-dex for R/R multiple myelomaПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

CyborD-DARA combination in first-line treatment for multiple myelomaПодробнее

ASH 2018: Dara/Rev/Dex/Velcade for Newly Diagnosed Multiple Myeloma PatientsПодробнее

MAIA: dara-len-dex demonstrates prolonged PFS in multiple myelomaПодробнее

Carfilzomib 2x Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and DexПодробнее

DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patientsПодробнее

$DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patients$

MRD negativity rates following carfilzomib, dex & dara in R/R myelomaПодробнее

GRIFFIN: follow-up after DARA + RVd for multiple myelomaПодробнее

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dex in Unfit and Frail NDMM PatientsПодробнее

Pomalidomide with dexamethasone in relapsed/refractory multiple myeloma with renal impairmentПодробнее

$Pomalidomide with dexamethasone in relapsed/refractory multiple myeloma with renal impairment$

Pom/dex combinations as salvage for myeloma R/R to daraПодробнее